Blending space and time to talk about cancer in extended reality.


Journal

NPJ digital medicine
ISSN: 2398-6352
Titre abrégé: NPJ Digit Med
Pays: England
ID NLM: 101731738

Informations de publication

Date de publication:
29 Sep 2024
Historique:
received: 17 12 2023
accepted: 18 09 2024
medline: 30 9 2024
pubmed: 30 9 2024
entrez: 29 9 2024
Statut: epublish

Résumé

We introduce a proof-of-concept extended reality (XR) environment for discussing cancer, presenting genomic information from multiple tumour sites in the context of 3D tumour models generated from CT scans. This tool enhances multidisciplinary discussions. Clinicians and cancer researchers explored its use in oncology, sharing perspectives on XR's potential for use in molecular tumour boards, clinician-patient communication, and education. XR serves as a universal language, fostering collaborative decision-making in oncology.

Identifiants

pubmed: 39343807
doi: 10.1038/s41746-024-01262-x
pii: 10.1038/s41746-024-01262-x
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

261

Subventions

Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765
Organisme : Manatu Hauora | Health Research Council of New Zealand (HRC)
ID : 20/765

Informations de copyright

© 2024. The Author(s).

Références

Sharp, P. A. & Langer, R. Promoting convergence in biomedical science. Science 333, 527–527 (2011).
pubmed: 21798916 doi: 10.1126/science.1205008
Rolfo, C. et al. Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer. ESMO Open 3, e000398 (2018).
pubmed: 30094075 pmcid: 6069914 doi: 10.1136/esmoopen-2018-000398
Moore, D. A. et al. Prospective analysis of 895 patients on a UK Genomics Review Board. ESMO Open 4, e000469 (2019).
pubmed: 31245058 pmcid: 6557082 doi: 10.1136/esmoopen-2018-000469
Dillekås, H., Rogers, M. S. & Straume, O. Are 90% of deaths from cancer caused by metastases? Cancer Med 8, 5574–5576 (2019).
pubmed: 31397113 pmcid: 6745820 doi: 10.1002/cam4.2474
Perakis, S. O. et al. Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer. ESMO Open 5, e000872 (2020).
pubmed: 32967919 pmcid: 7513637 doi: 10.1136/esmoopen-2020-000872
Lazebnik, Y. Can a biologist fix a radio? Or, what I learned while studying apoptosis. Cancer Cell 2, 179–182 (2002).
pubmed: 12242150 doi: 10.1016/S1535-6108(02)00133-2
Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).
pubmed: 24487277 pmcid: 4636053 doi: 10.1038/ng.2891
Robb, T. J. et al. Complex patterns of genomic heterogeneity identified in 42 tumor samples and ctDNA of a pulmonary atypical carcinoid patient. Cancer Res. Commun. 3, 31–42 (2023).
pubmed: 36968225 pmcid: 10035512 doi: 10.1158/2767-9764.CRC-22-0101
Hood, L. Systems biology and p4 medicine: past, present, and future. Rambam Maimonides Med. J. 4, e0012 (2013).
pubmed: 23908862 pmcid: 3678833 doi: 10.5041/RMMJ.10112
Blenkiron, C. et al. Tailoring a rapid autopsy protocol to explore cancer evolution: a patient collaboration. N. Z. Med. J. 132, 83–92 (2019).
pubmed: 31581185
Robb, T. J., Tse, R. & Blenkiron, C. Reviving the autopsy for modern cancer evolution research. Cancers 13, 409 (2021).
pubmed: 33499137 pmcid: 7866143 doi: 10.3390/cancers13030409
Pires, F., Costa, C. & Dias, P. On the use of virtual reality for medical imaging visualization. J. Digit Imaging 34, 1034–1048 (2021).
pubmed: 34327628 pmcid: 8455774 doi: 10.1007/s10278-021-00480-z
Yuan, J. et al. Extended reality for biomedicine. Nat. Rev. Methods Prim. 3, 14 (2023).
doi: 10.1038/s43586-023-00198-y
Wang, S. et al. Augmented reality as a telemedicine platform for remote procedural training. Sensors 17, 2294 (2017).
pubmed: 28994720 pmcid: 5676722 doi: 10.3390/s17102294
Pratt, P. et al. Through the HoloLens™ looking glass: augmented reality for extremity reconstruction surgery using 3D vascular models with perforating vessels. Eur. Radiol. Exp. 2, 2 (2018).
pubmed: 29708204 pmcid: 5909360 doi: 10.1186/s41747-017-0033-2
Ortiz-Catalan, M., Sander, N., Kristoffersen, M., Håkansson, B. & Brånemark, R. Treatment of phantom limb pain (PLP) based on augmented reality and gaming controlled by myoelectric pattern recognition: a case study of a chronic PLP patient. Front. Neurosci. 8, 71345 (2014).
doi: 10.3389/fnins.2014.00024
Sivananthan, A. et al. A feasibility trial of HoloLens 2™; using mixed reality headsets to deliver remote bedside teaching during COVID-19. Res. Sq. 6, e35674 (2021).
Lau, C. W. et al. Virtual reality for the observation of oncology models (VROOM): immersive analytics for oncology patient cohorts. Sci. Rep. 12, 11337 (2022).
pubmed: 35790803 pmcid: 9256599 doi: 10.1038/s41598-022-15548-1
Pirch, S. et al. The VRNetzer platform enables interactive network analysis in Virtual Reality. Nat. Commun. 12, 2432 (2021).
pubmed: 33893283 pmcid: 8065164 doi: 10.1038/s41467-021-22570-w
Robb, T. J. Tumour evolution in a single patient PhD thesis, University of Auckland, (2021).
Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404 (2012).
pubmed: 22588877 doi: 10.1158/2159-8290.CD-12-0095
Goldman, M. J. et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 38, 675–678 (2020).
pubmed: 32444850 pmcid: 7386072 doi: 10.1038/s41587-020-0546-8
Goldman, M. J. et al. A user guide for the online exploration and visualization of PCAWG data. Nat. Commun. 11, 3400 (2020).
pubmed: 32636365 pmcid: 7340791 doi: 10.1038/s41467-020-16785-6
Qu, Z., Lau, C. W., Nguyen, Q. V., Zhou, Y. & Catchpoole, D. R. Visual analytics of genomic and cancer data: a systematic review. Cancer Inform. 18, 1176935119835546 (2019).
pubmed: 30890859 pmcid: 6416684 doi: 10.1177/1176935119835546
Saadatmand, S., Bretveld, R., Siesling, S. & Tilanus-Linthorst, M. M. A. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ 351, h4901 (2015).
pubmed: 26442924 pmcid: 4595560 doi: 10.1136/bmj.h4901
Erdmann, J. All aboard: will molecular tumor boards help cancer patients? Nat. Med. 21, 655–656 (2015).
pubmed: 26151320 doi: 10.1038/nm0715-655
Kato, S. et al. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat. Commun. 11, 4965 (2020).
pubmed: 33009371 pmcid: 7532150 doi: 10.1038/s41467-020-18613-3
Repetto, M. et al. Molecular tumour board at European Institute of Oncology: report of the first three year activity of an Italian precision oncology experience. Eur. J. Cancer 183, 79–89 (2023).
pubmed: 36801623 doi: 10.1016/j.ejca.2023.01.019
Fittall, M. W. & Van Loo, P. Translating insights into tumor evolution to clinical practice: promises and challenges. Genome Med. 11, 20 (2019).
pubmed: 30925887 pmcid: 6440005 doi: 10.1186/s13073-019-0632-z
Pelanis, E. et al. Use of mixed reality for improved spatial understanding of liver anatomy. Minim. Invasive Ther. Allied Technol. 29, 154–160 (2020).
pubmed: 31116053 doi: 10.1080/13645706.2019.1616558
Pishvaian, M. J. et al. A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. JAMIA Open 2, 505–515 (2019).
pubmed: 32025647 pmcid: 6994017 doi: 10.1093/jamiaopen/ooz045
Russo, A. et al. The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: a position paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies. Crit. Rev. Oncol. Hematol. 169, 103567 (2022).
pubmed: 34896250 doi: 10.1016/j.critrevonc.2021.103567
Dodds, H. E. Immersive learning environments: designing XR into higher education.A Practitioner’s. Guide Instr. Des. High. Educ. 1, 69–79 (2021).
doi: 10.59668/164.4220
Zweifach, S. M. & Triola, M. M. Extended reality in medical education: driving adoption through provider-centered design. Digital Biomark. 3, 14–21 (2019).
doi: 10.1159/000498923
Lee, Y. & Yoo, B. XR collaboration beyond virtual reality: work in the real world. J. Comput. Des. Eng. 8, 756–772 (2021).
Khader, J. Improving cancer outcomes through international collaboration in developing countries: King Hussein Cancer Center as a unique experience. J. Glob. Oncol. 4, 161s–161s (2018).
doi: 10.1200/jgo.18.43300
Carlin, L. E., Smith, H. E. & Henwood, F. To see or not to see: a qualitative interview study of patients’ views on their own diagnostic images. BMJ open 4, e004999 (2014).
pubmed: 25082418 pmcid: 4120403 doi: 10.1136/bmjopen-2014-004999
Phelps, E. E., Wellings, R., Griffiths, F., Hutchinson, C. & Kunar, M. Do medical images aid understanding and recall of medical information? An experimental study comparing the experience of viewing no image, a 2D medical image and a 3D medical image alongside a diagnosis. Patient Educ. Couns. 100, 1120–1127 (2017).
pubmed: 28081938 doi: 10.1016/j.pec.2016.12.034
Mulsow, J. J. W., Feeley, T. M. & Tierney, S. Beyond consent—improving understanding in surgical patients. Am. J. Surg. 203, 112–120 (2012).
pubmed: 21641573 doi: 10.1016/j.amjsurg.2010.12.010
Falagas, M. E., Korbila, I. P., Giannopoulou, K. P., Kondilis, B. K. & Peppas, G. Informed consent: how much and what do patients understand? Am. J. Surg. 198, 420–435 (2009).
pubmed: 19716887 doi: 10.1016/j.amjsurg.2009.02.010
Perin, A. et al. Informed consent through 3D virtual reality: a randomized clinical trial. Acta Neurochir. 163, 301–308 (2021).
pubmed: 32242272 doi: 10.1007/s00701-020-04303-y
Miller, S. M. Monitoring versus blunting styles of coping with cancer influence the information patients want and need about their disease. Implications for cancer screening and management. Cancer 76, 167–177 (1995).
pubmed: 8625088 doi: 10.1002/1097-0142(19950715)76:2<167::AID-CNCR2820760203>3.0.CO;2-K
Stepan, K. et al. Immersive virtual reality as a teaching tool for neuroanatomy. Int. Forum Allergy Rhinol. 7, 1006–1013 (2017).
pubmed: 28719062 doi: 10.1002/alr.21986
Makransky, G., Terkildsen, T. S. & Mayer, R. E. Adding immersive virtual reality to a science lab simulation causes more presence but less learning. Learn. Instr. 60, 225–236 (2019).
doi: 10.1016/j.learninstruc.2017.12.007
Robertson, S. P. et al. Genomic medicine must reduce, not compound, health inequities: the case for hauora-enhancing genomic resources for New Zealand. N. Z. Med. J. 131, 81–89 (2018).
pubmed: 30116069
Madhusoodanan, J. Health-care inequality could deepen with precision oncology. Nature 585, S13–S13 (2020).
doi: 10.1038/d41586-020-02678-7
Henare, K. L. et al. Mapping a route to Indigenous engagement in cancer genomic research. Lancet Oncol. 20, e327–e335 (2019).
pubmed: 31162106 doi: 10.1016/S1470-2045(19)30307-9
Dal Mas, F., Massaro, M., Rippa, P. & Secundo, G. The challenges of digital transformation in healthcare: An interdisciplinary literature review, framework, and future research agenda. Technovation 123, 102716 (2023).
doi: 10.1016/j.technovation.2023.102716
Ting, D. S. W., Carin, L., Dzau, V. & Wong, T. Y. Digital technology and COVID-19. Nat. Med. 26, 459–461 (2020).
pubmed: 32284618 pmcid: 7100489 doi: 10.1038/s41591-020-0824-5
NHS England & NHS Improvement. Science in healthcare: Delivering the NHS long term plan. The Chief Scientific Officer’s strategy, https://www.england.nhs.uk/wp-content/uploads/2020/03/science-in-healthcare-delivering-the-nhs-long-term-plan.pdf (2020).
Vlčková, J. & Klimková, V. The digital transformation of Czech healthcare: trends and COVID-19 impact. Int. J. Electron. Healthc. 13, 15–32 (2023).
doi: 10.1504/IJEH.2023.128604
Nan, C., Pradosh, K. & Viktor, G. Augmented reality with Microsoft HoloLens holograms for near infrared fluorescence based image guided surgery. Proc.SPIE 10049, https://doi.org/10.1117/12.2251625, (2017).
Poothicottu Jacob, G. A HoloLens Framework for Augmented Reality Applications in Breast Cancer Surgery Master of Applied Science thesis, University of Waterloo, (2018).
Zafar, S. & Zachar, J. J. Evaluation of HoloHuman augmented reality application as a novel educational tool in dentistry. Eur. J. Dent. Educ. 24, 259–265 (2020).
pubmed: 31899840 doi: 10.1111/eje.12492
Hillary, L. et al. HoloLens in suturing training. Proc.SPIE 10576, https://doi.org/10.1117/12.2293934, (2018).
Luck, J., Gosling, N. & Saour, S. Undergraduate surgical education during COVID-19: could augmented reality provide a solution? Br. J. Surg. 108, e129–e130 (2021).
pubmed: 33793706 doi: 10.1093/bjs/znaa159
Tu, P. et al. Augmented reality based navigation for distal interlocking of intramedullary nails utilizing Microsoft HoloLens 2. Comput. Biol. Med. 133, 104402 (2021).
pubmed: 33895460 doi: 10.1016/j.compbiomed.2021.104402
Liimatainen, K., Latonen, L., Valkonen, M., Kartasalo, K. & Ruusuvuori, P. Virtual reality for 3D histology: multi-scale visualization of organs with interactive feature exploration. BMC Cancer 21, 1133 (2021).
pubmed: 34686173 pmcid: 8539837 doi: 10.1186/s12885-021-08542-9

Auteurs

Tamsin J Robb (TJ)

Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Yinan Liu (Y)

School of Architecture and Planning, University of Auckland, Auckland, New Zealand.

Braden Woodhouse (B)

Department of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Charlotta Windahl (C)

Business School, University of Auckland, Auckland, New Zealand.

Daniel Hurley (D)

Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Grant McArthur (G)

University of Melbourne, Melbourne, VIC, Australia.
Victorian Comprehensive Cancer Centre Alliance, Melbourne, VIC, Australia.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Stephen B Fox (SB)

University of Melbourne, Melbourne, VIC, Australia.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

Lisa Brown (L)

University of Melbourne, Melbourne, VIC, Australia.
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
The Royal Melbourne Hospital, Melbourne, VIC, Australia.

Parry Guilford (P)

University of Otago, Dunedin, New Zealand.

Alice Minhinnick (A)

Department of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Auckland City Hospital, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.

Christopher Jackson (C)

University of Otago, Dunedin, New Zealand.

Cherie Blenkiron (C)

Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.

Kate Parker (K)

Department of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Kimiora Henare (K)

Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand.

Rose McColl (R)

Centre for eResearch, University of Auckland, Auckland, New Zealand.

Bianca Haux (B)

Centre for eResearch, University of Auckland, Auckland, New Zealand.

Nick Young (N)

Centre for eResearch, University of Auckland, Auckland, New Zealand.

Veronica Boyle (V)

School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Laird Cameron (L)

Auckland City Hospital, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.

Sanjeev Deva (S)

Auckland City Hospital, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.

Jane Reeve (J)

Radiology Auckland, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand.

Cristin G Print (CG)

Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Michael Davis (M)

School of Architecture and Planning, University of Auckland, Auckland, New Zealand.

Uwe Rieger (U)

School of Architecture and Planning, University of Auckland, Auckland, New Zealand.

Ben Lawrence (B)

Department of Oncology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand. b.lawrence@auckland.ac.nz.
Auckland City Hospital, Te Whatu Ora Te Toka Tumai, Auckland, New Zealand. b.lawrence@auckland.ac.nz.

Classifications MeSH